Stock Market Reviews

ARMP (Armata Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on ARMP (Armata Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
  Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
  Oct 6, 2025 - $ARMP
• Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
  Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
  Sep 18, 2025 - $ARMP
• Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology
  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology (JMB).
  Sep 8, 2025 - $ARMP
• Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held in New Yor
  Sep 4, 2025 - $ARMP
• Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
  Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
  Sep 1, 2025 - $ARMP
• All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
  Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Aug 15, 2025 - $ARMP
• Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
  Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.
  Aug 15, 2025 - $ARMP
• Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates
  Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025 - $ARMP
• Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update
  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update.
  Aug 12, 2025 - $ARMP
• Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
  Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced positive topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous ("IV") administered multi-phage therapeutic for the treatment of Staphylococcus aureus
  May 19, 2025 - $ARMP